Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOXIRI vs Immediate Surgery for High-risk Colon Cancer
NCT05194878Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Disease-free survival at 2 years. Started Dec 2021; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05194878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194878.